Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Discloses Diagnostic, Therapeutic-development Timelines for 06- 07

NEW YORK, Nov. 9 (GenomeWeb News) - Compugen expects to develop products during the next two years based on initial discoveries, the company's CEO said today at a conference.


Speaking at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference, held here this week, Martin Gerstel said Compugen over 2006 and 2007 will be developing products based on the first wave of discoveries in immunoassay diagnostics, nucleic acid diagnostics, and therapeutic protein candidates. The company is also looking for a proof of concept for a new technology platform.


Product development agreements for immunoassay diagnostics, the company's most advanced product area, have already been signed with three diagnostic companies, such as BioSite.


Nucleic acid diagnostics are "about a year behind our immunoassay activities," said Gerstel. The company expects to negotiate nucleic acid development and commercialization agreements beginning in the second half of 2006.


Partners for therapeutic protein candidates will also be signed during the second half of 2006, according to Gerstel.


While focusing on product development in the next two years, Compugen will continue discovery activities targeted at cancer and cardiovascular diseases. A significant area of expenditure within R&D would focus on in vitro and in vivo activities for the therapeutic protein pipeline. The company also expects to demonstrate a proof of concept for a new platform that can be achieved within 9-12 months and addresses a bottleneck in drug discovery.


"The further development and commercialization of this new platform would be the subject of a major collaboration with a pharma or biotech partner," Gerstel said.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.